Emerging Treatment Options for Patients with NSCLC with ALK Rearrangements
Experts on non–small cell lung cancer discuss recent data on brigatinib and lorlatinib for the treatment of patients with ALK rearrangements.
Biomarker Testing Targeted Therapies Treatment Options Non Small Cell Lung Cancer Alk Rearrangements Alta 1l
Source: onclive.com